F

Fresenius Medical Care AG & Co KGaA
XETRA:FME

Watchlist Manager
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Watchlist
Price: 42.25 EUR 1.95% Market Closed
Market Cap: 12.4B EUR
Have any thoughts about
Fresenius Medical Care AG & Co KGaA?
Write Note

Fresenius Medical Care AG & Co KGaA
Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Fresenius Medical Care AG & Co KGaA
Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
F
Fresenius Medical Care AG & Co KGaA
XETRA:FME
Long-Term Debt
€10.3B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
5%
Fresenius SE & Co KGaA
XETRA:FRE
Long-Term Debt
€11.5B
CAGR 3-Years
-20%
CAGR 5-Years
-12%
CAGR 10-Years
-1%
Vita 34 AG
XETRA:V3V
Long-Term Debt
€12.7m
CAGR 3-Years
76%
CAGR 5-Years
20%
CAGR 10-Years
28%
E
Euroeyes International Eye Clinic Ltd
HKEX:1846
Long-Term Debt
HK$313.5m
CAGR 3-Years
19%
CAGR 5-Years
12%
CAGR 10-Years
N/A
Synlab AG
XETRA:SYAB
Long-Term Debt
€1.4B
CAGR 3-Years
-23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Fresenius Medical Care AG
XMUN:FME
Long-Term Debt
€10.3B
CAGR 3-Years
0%
CAGR 5-Years
1%
CAGR 10-Years
5%
No Stocks Found

Fresenius Medical Care AG & Co KGaA
Glance View

Market Cap
12.4B EUR
Industry
Health Care

Fresenius Medical Care AG & Co KGaA emerged as a global leader in providing products and services for individuals undergoing dialysis, primarily due to chronic kidney disease (CKD). Founded in 1996 and headquartered in Bad Homburg, Germany, the company operates in over 120 countries, serving millions of patients while showcasing a commitment to innovation in renal care. By combining advanced medical technologies with a robust network of outpatient dialysis clinics, Fresenius has positioned itself as a vital player in the healthcare sector. Its commitment to high-quality patient care and effective treatment solutions not only sets it apart but also aligns with the increasing global demand for healthcare services, particularly relevant as the world faces an aging population and rising prevalence of kidney-related conditions. For investors, Fresenius Medical Care represents a compelling opportunity within the expanding healthcare market. The company has demonstrated consistent revenue growth and a resilient business model, generating substantial cash flow, which it reinvests into research and development. This focus on innovation and operational excellence enhances its competitive edge, enabling it to respond swiftly to changes in healthcare regulations and patient needs. With strategic partnerships and integrated care solutions, Fresenius Medical Care is not just navigating the complexities of the healthcare landscape but thriving in it, making it an attractive investment for those looking to enter a sector poised for growth amid increasing global health challenges.

FME Intrinsic Value
80.86 EUR
Undervaluation 48%
Intrinsic Value
Price
F

See Also

What is Fresenius Medical Care AG & Co KGaA's Long-Term Debt?
Long-Term Debt
10.3B EUR

Based on the financial report for Jun 30, 2024, Fresenius Medical Care AG & Co KGaA's Long-Term Debt amounts to 10.3B EUR.

What is Fresenius Medical Care AG & Co KGaA's Long-Term Debt growth rate?
Long-Term Debt CAGR 10Y
5%

Over the last year, the Long-Term Debt growth was -4%.

Back to Top